149 related articles for article (PubMed ID: 32879375)
1. Importance of structure-based studies for the design of a novel HIV-1 inhibitor peptide.
Gomara MJ; Perez Y; Gomez-Gutierrez P; Herrera C; Ziprin P; Martinez JP; Meyerhans A; Perez JJ; Haro I
Sci Rep; 2020 Sep; 10(1):14430. PubMed ID: 32879375
[TBL] [Abstract][Full Text] [Related]
2. Structural Study of a New HIV-1 Entry Inhibitor and Interaction with the HIV-1 Fusion Peptide in Dodecylphosphocholine Micelles.
Pérez Y; Gómara MJ; Yuste E; Gómez-Gutierrez P; Pérez JJ; Haro I
Chemistry; 2017 Aug; 23(48):11703-11713. PubMed ID: 28677862
[TBL] [Abstract][Full Text] [Related]
3. Short constrained peptides that inhibit HIV-1 entry.
Sia SK; Carr PA; Cochran AG; Malashkevich VN; Kim PS
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14664-9. PubMed ID: 12417739
[TBL] [Abstract][Full Text] [Related]
4. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
5. Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.
Herrera E; Tenckhoff S; Gómara MJ; Galatola R; Bleda MJ; Gil C; Ercilla G; Gatell JM; Tillmann HL; Haro I
J Med Chem; 2010 Aug; 53(16):6054-63. PubMed ID: 20718496
[TBL] [Abstract][Full Text] [Related]
6. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides.
Shu W; Liu J; Ji H; Radigen L; Jiang S; Lu M
Biochemistry; 2000 Feb; 39(7):1634-42. PubMed ID: 10677212
[TBL] [Abstract][Full Text] [Related]
7. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
Zhu Y; Ding X; Yu D; Chong H; He Y
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles.
DeMarco SJ; Henze H; Lederer A; Moehle K; Mukherjee R; Romagnoli B; Robinson JA; Brianza F; Gombert FO; Lociuro S; Ludin C; Vrijbloed JW; Zumbrunn J; Obrecht JP; Obrecht D; Brondani V; Hamy F; Klimkait T
Bioorg Med Chem; 2006 Dec; 14(24):8396-404. PubMed ID: 17010618
[TBL] [Abstract][Full Text] [Related]
9. Macrocyclic Envelope Glycoprotein Antagonists that Irreversibly Inactivate HIV-1 before Host Cell Encounter.
Rashad AA; Kalyana Sundaram RV; Aneja R; Duffy C; Chaiken I
J Med Chem; 2015 Sep; 58(18):7603-8. PubMed ID: 26331669
[TBL] [Abstract][Full Text] [Related]
10. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
11. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication.
Hamy F; Felder ER; Heizmann G; Lazdins J; Aboul-ela F; Varani G; Karn J; Klimkait T
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3548-53. PubMed ID: 9108013
[TBL] [Abstract][Full Text] [Related]
12. Peptide Assembly on the Membrane Determines the HIV-1 Inhibitory Activity of Dual-Targeting Fusion Inhibitor Peptides.
Gomara MJ; Perez Y; Martinez JP; Barnadas-Rodriguez R; Schultz A; von Briesen H; Peralvarez-Marin A; Meyerhans A; Haro I
Sci Rep; 2019 Mar; 9(1):3257. PubMed ID: 30824796
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.
Eckert DM; Malashkevich VN; Hong LH; Carr PA; Kim PS
Cell; 1999 Oct; 99(1):103-15. PubMed ID: 10520998
[TBL] [Abstract][Full Text] [Related]
14. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core.
Zhou G; Ferrer M; Chopra R; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Harrison SC; Wiley DC
Bioorg Med Chem; 2000 Sep; 8(9):2219-27. PubMed ID: 11026535
[TBL] [Abstract][Full Text] [Related]
15. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
16. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
Tamamura H; Xu Y; Hattori T; Zhang X; Arakaki R; Kanbara K; Omagari A; Otaka A; Ibuka T; Yamamoto N; Nakashima H; Fujii N
Biochem Biophys Res Commun; 1998 Dec; 253(3):877-82. PubMed ID: 9918823
[TBL] [Abstract][Full Text] [Related]
17. Short peptides with induced beta-turn inhibit the interaction between HIV-1 gp120 and CD4.
Choi YH; Rho WS; Kim ND; Park SJ; Shin DH; Kim JW; Im SH; Won HS; Lee CW; Chae CB; Sung YC
J Med Chem; 2001 Apr; 44(9):1356-63. PubMed ID: 11311058
[TBL] [Abstract][Full Text] [Related]
18. Protein design of an HIV-1 entry inhibitor.
Root MJ; Kay MS; Kim PS
Science; 2001 Feb; 291(5505):884-8. PubMed ID: 11229405
[TBL] [Abstract][Full Text] [Related]
19. Is the conformational flexibility of piperazine derivatives important to inhibit HIV-1 replication?
Teixeira C; Serradji N; Amroune S; Storck K; Rogez-Kreuz C; Clayette P; Barbault F; Maurel F
J Mol Graph Model; 2013 Jul; 44():91-103. PubMed ID: 23748247
[TBL] [Abstract][Full Text] [Related]
20. A covalent inhibitor targeting an intermediate conformation of the fusogenic subunit of the HIV-1 envelope complex.
Jacobs A; Quraishi O; Huang X; Bousquet-Gagnon N; Nault G; Francella N; Alvord WG; Pham N; Soucy C; Robitaille M; Bridon D; Blumenthal R
J Biol Chem; 2007 Nov; 282(44):32406-13. PubMed ID: 17726011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
